Lack of data leads to double NICE no for Novartis's Glivec
This article was originally published in Scrip
NICE, the National Institute for health and Clinical Excellence in the UK, is set to decline NHS funding for high doses of Novartis's Glivec (imatinib) for treating unresectable and or metastatic gastrointestinal stromal tumors (GIST), it says in preliminary draft guidance published today. It based the decision on a lack of "good quality clinical and cost-effectiveness data".
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.